MAST3 Antibody

What is MAST3 and what are its key biological functions?

MAST3 (Microtubule Associated Serine/Threonine Kinase 3) is a member of the MAST family of serine/threonine kinases with a molecular weight of approximately 143 kDa. It functions as a modulator of inflammatory responses through regulation of immune gene expression, particularly in the gut of IBD patients . MAST3 plays a significant role in modulating NF-κB activity, a key transcription factor in inflammation . Recent research has revealed that MAST3 is predominantly expressed in the human cortex, hippocampus, and striatum, suggesting important neurological functions . Mechanistically, MAST3 has been implicated in the coordination of cAMP/protein kinase A/protein phosphatase 2A signaling pathways that mediate the effects of dopamine in adult rodent striatal medium spiny neurons .

How does MAST3 differ from other members of the MAST kinase family?

While most members of the MAST family are ubiquitously expressed with highest expression in the brain , MAST3 has distinct expression patterns in developing and mature human and mouse brain compared to other family members. Unlike MAST1, which has been associated with neurodevelopmental disorders featuring mega corpus callosum, MAST3 has been implicated in developmental and epileptic encephalopathies (DEEs) with different clinical presentations . MAST3 is also specifically involved in inflammatory bowel disease as a genetic risk factor, identified through association fine-mapping of the chromosome 19p region (also known as linkage region IBD6) . From a structural perspective, MAST3 contains a highly conserved serine-threonine kinase (STK) domain that exhibits intolerance to variation, with missense tolerance ratio scores below the 25th percentile .

What criteria should guide selection of a MAST3 antibody for specific experimental applications?

When selecting a MAST3 antibody, researchers should consider:

Thoroughly examine the validation data provided by manufacturers, particularly looking for detection in tissue types relevant to your research. For example, antibody 19507-1-AP has been validated in Jurkat cells, human brain tissue, mouse and rat brain tissues, making it suitable for neurological studies .

How should MAST3 antibodies be validated before use in critical experiments?

A comprehensive validation strategy for MAST3 antibodies should include:

• Positive and negative control tissues/cells: Use tissues known to express MAST3 (brain, kidney) versus those with minimal expression.

• Molecular weight verification: Confirm detection at the expected molecular weight of 143-144 kDa in Western blot applications .

• Overexpression validation: Express tagged MAST3 constructs (as done in research with MAST3-HA expressed in HEK293T cells) to confirm antibody specificity .

• Knockdown experiments: Perform siRNA or shRNA knockdown of MAST3 to validate reduction of signal with the antibody, similar to approaches used in published MAST3 studies .

• Cross-reactivity testing: Especially important when studying multiple MAST family members simultaneously to ensure specificity.

• Multi-application concordance: Verify that the antibody's detection pattern is consistent across different applications (e.g., regions positive by IHC should align with WB data from the same tissue).

For neurological studies, validation in brain tissue sections using immunofluorescence with established neuronal markers (as done with CUX1, SATB2, TBR1, and CTIP2) provides additional confidence in antibody specificity .

What are the optimal protocols for using MAST3 antibodies in Western blot applications?

For optimal Western blot detection of MAST3 (143 kDa protein):

• Sample preparation:

  • For cell lines: Lyse cells in RIPA buffer containing protease inhibitors (Complete Mini EDTA-Free), followed by brief sonication and centrifugation at 14,000 × g for 5 min at 4°C .

  • For tissues: Homogenize in TBS + 1% Triton X-100 with protease inhibitors.

• Gel electrophoresis:

  • Use 4-20% Tris-HCl gradient gels to adequately separate high molecular weight proteins .

  • Load 15-20 μg protein per lane for cell lysates, 30-50 μg for tissue samples.

• Transfer conditions:

  • For large proteins like MAST3, use wet transfer to nitrocellulose membranes (0.45 μm pore size).

  • Transfer at 30V overnight at 4°C for improved efficiency of large proteins.

• Antibody incubation:

  • Block with 2-5% non-fat dry milk in TBS.

  • Incubate with primary MAST3 antibody at 1:500-1:3000 dilution (based on antibody specifications ) overnight at 4°C.

  • Wash thoroughly (3-5 times, 5 minutes each) with TBST.

  • Incubate with appropriate HRP-conjugated or fluorescent-labeled secondary antibodies.

• Detection:

  • For chemiluminescence: Use enhanced ECL detection systems given the relatively low abundance of MAST3 in many tissues.

  • For fluorescence: Use systems like LiCor Odyssey with IRDye 680RD/800CW secondary antibodies (1:20,000 dilution) .

What methods are available for studying MAST3 kinase activity in experimental settings?

Several approaches have been validated for studying MAST3 kinase activity:

• In vitro kinase assays with recombinant ARPP-16:

  • ARPP-16 is an established substrate for MAST3 .

  • Immunoprecipitate MAST3 (using HA-tagged constructs or endogenous protein).

  • Incubate immunoprecipitated MAST3 with ARPP-16 in kinase reaction buffer containing ATP.

  • Detect phosphorylation using phospho-specific antibodies (e.g., pS46 ARPP-16 antibody) .

• Phosphorylation detection in cell-based systems:

  • Co-transfect HEK293T cells with MAST3 constructs (wild-type or variants) and ARPP-16.

  • Measure ARPP-16 phosphorylation via immunoblotting with phospho-specific antibodies.

  • Normalize phosphorylation levels to MAST3 expression levels .

• PKA regulation of MAST3 activity:

  • Treat cells with forskolin (10 μM, 30 minutes) to activate PKA.

  • Immunoprecipitate MAST3 and perform LC-MS/MS analysis to identify phosphorylation sites.

  • Study how PKA-dependent phosphorylation affects MAST3's kinase activity toward ARPP-16 .

• Overexpression and knockdown approaches:

  • Express MAST3 in HEK293 cells and analyze genome-wide gene expression changes via microarray.

  • Perform knockdown of MAST3 in relevant cell types (e.g., THP1 immune cells) to confirm specificity of gene expression changes .

How can researchers accurately study the interactions between MAST3 and NF-κB signaling pathways?

To investigate MAST3-NF-κB pathway interactions:

• NF-κB reporter assays:

  • Transfect cells with an NF-κB luciferase reporter construct.

  • Co-transfect with MAST3 wild-type, kinase-dead mutants (e.g., K396H), or disease-associated variants.

  • Stimulate cells with TLR4 activators as MAST3 knockdown has been shown to specifically decrease TLR4-stimulated NF-κB activity .

  • Measure luminescence as a readout of NF-κB transcriptional activity.

• Target gene expression analysis:

  • Focus on established MAST3-regulated genes that are modulated by NF-κB, including pro-inflammatory cytokines (CCL20, IL8), regulators of NF-κB (TNFAIP3, LY96, NFKBIA), and interferon-induced genes (IFIT1, ISG15) .

  • Use RT-qPCR to measure expression changes in response to MAST3 modulation.

  • Confirm NF-κB dependency using NF-κB inhibitors or dominant-negative IκB constructs.

• NF-κB nuclear translocation assays:

  • Employ immunofluorescence with antibodies against NF-κB p65 subunit.

  • Quantify nuclear/cytoplasmic ratios of p65 signal in cells with manipulated MAST3 expression.

  • Use high-content imaging for high-throughput analysis.

• Phosphorylation analysis of NF-κB pathway components:

  • Analyze phosphorylation status of IKK complex, IκB, and p65 in response to MAST3 overexpression or knockdown.

  • Use phospho-specific antibodies in Western blot or immunofluorescence assays.

• Co-immunoprecipitation studies:

  • Identify direct interactions between MAST3 and NF-κB pathway components.

  • Use epitope-tagged constructs or antibodies against endogenous proteins.

  • Validate interactions using reciprocal co-IPs and proximity ligation assays.

What are the common pitfalls when working with MAST3 antibodies and how can researchers overcome them?

For troubleshooting variable results in immunofluorescence applications, researchers have successfully employed counterstaining with Hoechst 33342 for nuclei visualization and have mounted samples with ProLong Gold Antifade to preserve fluorescence signals .

How can researchers effectively study MAST3 mutations associated with epileptic encephalopathies?

To investigate MAST3 mutations in epileptic encephalopathies:

• Functional characterization of patient variants:

  • Create expression constructs containing patient-specific missense variants (e.g., G510S, G515S) in the STK domain .

  • Express these variants in cellular models and assess:

    • Protein expression levels

    • Subcellular localization

    • Kinase activity toward ARPP-16

    • Effects on downstream signaling pathways

• Neuronal expression pattern analysis:

  • Use single-nuclei RNA sequencing to determine cell-type specific expression of MAST3.

  • Perform immunohistochemistry with MAST3 antibodies alongside neuronal markers (CUX1, SATB2, TBR1, CTIP2) in brain sections .

  • Compare expression patterns between control and patient samples when available.

• In vitro modeling using patient-derived cells:

  • Generate induced pluripotent stem cells (iPSCs) from patients with MAST3 mutations.

  • Differentiate iPSCs into relevant neuronal subtypes.

  • Assess electrophysiological properties, morphology, and gene expression profiles.

• Animal models of MAST3 variants:

  • Create knock-in mouse models carrying equivalent mutations to those found in patients.

  • Assess seizure susceptibility, neurodevelopmental milestones, and behavioral phenotypes.

  • Perform ex vivo electrophysiology to understand circuit-level effects.

• Therapeutic screening:

  • Use cellular models expressing mutant MAST3 to screen for compounds that normalize phosphorylation of targets.

  • Test approved anti-epileptic drugs for efficacy in MAST3 mutant models.

What methodologies are most effective for studying MAST3's role in inflammatory bowel disease?

For investigating MAST3's role in IBD:

• Gene expression profiling approaches:

  • Compare expression of MAST3-regulated genes in inflamed versus non-inflamed tissues from UC patients.

  • Focus on genes known to be modulated by MAST3, including pro-inflammatory cytokines (CCL20, IL8), regulators of NF-κB (TNFAIP3, LY96, NFKBIA), and interferon-induced genes (IFIT1, ISG15) .

  • Use microarray or RNA-seq technologies for comprehensive profiling.

• Cell type-specific analyses:

  • Study MAST3 function in both epithelial cells (using models like HEK293) and immune cells (such as THP1 macrophages) .

  • Use cell sorting techniques to isolate specific intestinal cell populations from patient samples.

  • Analyze MAST3 expression and activity in each cell type.

• Ex vivo tissue culture systems:

  • Establish organoid cultures from patient biopsies.

  • Manipulate MAST3 expression using viral vectors or CRISPR-Cas9 technology.

  • Assess inflammatory responses and barrier function.

• Genetic association studies:

  • Expand on the existing genetic fine-mapping of the 19p linkage region (IBD6) .

  • Perform deeper sequencing of MAST3 in larger IBD cohorts.

  • Analyze gene-gene interactions between MAST3 and other IBD risk genes.

• Experimental colitis models:

  • Use MAST3 knockout or transgenic mice in established colitis models (DSS, TNBS, T-cell transfer).

  • Assess clinical parameters, histopathology, and inflammatory markers.

  • Analyze intestinal permeability and immune cell infiltration.

The expression of MAST3-regulated genes has been found to be enriched in inflamed mucosal tissue of UC patients, confirming their importance in IBD. This enrichment can be used as a marker to validate experimental interventions targeting MAST3 in disease models .